Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative mupirocin and chlorhexidine for prevention of deep surgical site infection after primary hip or knee arthroplasty
NL-OMON20376Phase 4Withdrawn
- Sponsor
- Isala
- Start
- Nov 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mupirocin and chlorhexidine in surgical site infection (SSI) and periprosthetic joint infection (PJI) (2 arms), sponsored by Isala. Primary endpoint: Deep postoperative wound infection at 1 year. Planned start Nov 2015; status: withdrawn.
02
Drugs
mupirocinchlorhexidine
03
Conditions
surgical site infection (SSI)periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NL-OMON20376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20376.